ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine-Reference-Cited by-同舟云学术

ERK Inhibitor LY3214996 Targets ERK Pathway–Driven Cancers: A Therapeutic Approach Toward Precision Medicine

Published:2019-11-19 Issue:2 Volume:19 Page:325-336
ISSN:1535-7163
Container-title:Molecular Cancer Therapeutics
language:en
Short-container-title:Mol Cancer Ther

Author:

Bhagwat Shripad V.,McMillen William T.,Cai Shufen,Zhao Baohui,Whitesell Matthew,Shen Weihua,Kindler Lisa,Flack Robert S.,Wu Wenjuan,Anderson Bryan,Zhai Yan,Yuan Xiu-Juan,Pogue Meghann,Van Horn Robert D.,Rao Xi,McCann Denis,Dropsey Andrew J.,Manro Jason,Walgren Jennie,Yuen Eunice,Rodriguez Michael J.,Plowman Gregory D.,Tiu Ramon V.,Joseph Sajan,Peng Sheng-Bin

Funder

Eli Lilly and Company

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Cited by 74 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A NRAS mRNA G-quadruplex structure-targeting small-molecule ligand reactivating DNA damage response in human cancer cells for combination therapy with clinical PI3K inhibitors;International Journal of Biological Macromolecules;2024-11

2. The ERK inhibitor GDC-0994 selectively inhibits growth of BRAF mutant cancer cells;Translational Oncology;2024-07

3. Inhibiting the Extracellular Signal-regulated Kinase 1/2 (ERK1/2) Cascade in Cancer and the Heart: for Better or Worse, in Sickness and Health?;International Journal of Drug Discovery and Pharmacology;2024-05-23

4. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer;International Journal of Molecular Sciences;2024-04-24

5. Combinatorial strategies to target RAS-driven cancers;Nature Reviews Cancer;2024-04-16